Comparison of the efficacy and adverse effects of visipaque and Ultravist in Contrast-enhanced CT Scan

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138904144316N1

Enrollment

120

Registered

2011-01-08

Start date

2009-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All of patients referred to abdominal and pelvic CT.

Interventions

injection contrast ultravist 300mgI/ml

Intervention 1: injection contrast ultravist 300mgI/ml. Intervention 2: injection contrast of visi paque300mgI/ml.

Diagnosis

injection contrast of visi paque300mgI/ml

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria : patients reffered for abdomenoplevic CT Exclusion criteria : renal disease, Diabetes, known drug reaction

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Increasing of contrast enhancement. Timepoint: 60 seconds after injection. Method of measurement: dansitometry with CTscan appratus.	—

Secondary

Measure	Time frame
Complication post injection. Timepoint: To one week after injection. Method of measurement: registrationin questionare.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Farideh Gharekhanloo

Hamedan University of Medical sciences

f_gharekhanloo@umsha.ac.ir+98 81 1264 0064

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026